Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Advertisement
Set Alert for Articles By Ramsey Baghdadi

Latest From Ramsey Baghdadi

Louisiana Purchase: State Eager To Test “Netflix Model” For Rx Spending

A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?
Pricing Debate Medicaid

REDUCE-IT Will Test Risks Of Weakening Protection Of FDA-Labeled Claims

Amarin spent five years and lots of money to show Vascepa reduced the risk of cardiovascular events. REDUCE-IT trial results will test what Amarin will get for conducting the trial and whether the company’s off-label argument could work against them. 
Advertising, Marketing & Sales Commercial

Medicare's CAR-T Panel Underscores Hurdles For PROs – And FDA/CMS Collaboration

MEDCAC meeting demonstrates complexity of patient-reported outcomes and place for PROs in regulatory decision-making compared to coverage.
Medicare Clinical Trials

Subsys Makes A Bad Impression On FDA REMS Panel Members

CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.

Regulation Risk Management

HHS Part B Plan Gets Pharma's Attention, But Savings Target May Be Too High

Regeneron analysis of policy's potential impact on Eylea signals that MA plans will face overwhelming challenge to achieve 20% savings in Part B. 
Pricing Debate Medicare

The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?

Akcea’s volanesorsen for familial chylomicronemia syndrome barely made it through advisory committee due to a rare but unpredictable and rapidly presenting adverse event that likely can’t be resolved with a REMS. Now what? 
Advisory Committees Drug Safety
See All
Advertisement
UsernamePublicRestriction

Register